BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 23327959)

  • 41. Low dose Rituximab for pre-emptive treatment of Epstein Barr virus reactivation after allogenic hematopoietic stem cell transplantation.
    Delapierre B; Reman O; Dina J; Breuil C; Bellal M; Johnson-Ansah H; Gac AC; Damaj G; Chantepie S
    Curr Res Transl Med; 2019 Nov; 67(4):145-148. PubMed ID: 30871955
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sustained response to intrathecal rituximab in EBV associated Post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant.
    Bonney DK; Htwe EE; Turner A; Kelsey A; Shabani A; Hughes S; Hughes I; Wynn RF
    Pediatr Blood Cancer; 2012 Mar; 58(3):459-61. PubMed ID: 21584931
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A prospective study on modulation of immunosuppression for Epstein-Barr virus reactivation in pediatric patients who underwent unrelated hematopoietic stem-cell transplantation.
    Cesaro S; Pegoraro A; Tridello G; Calore E; Pillon M; Varotto S; Abate D; Barzon L; Mengoli C; Carli M; Messina C
    Transplantation; 2010 Jun; 89(12):1533-40. PubMed ID: 20463647
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT.
    Dominietto A; Tedone E; Soracco M; Bruno B; Raiola AM; Van Lint MT; Geroldi S; Lamparelli T; Galano B; Gualandi F; Frassoni F; Bacigalupo A
    Bone Marrow Transplant; 2012 Jan; 47(1):101-6. PubMed ID: 21460867
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's Oncology Group Report.
    Gross TG; Orjuela MA; Perkins SL; Park JR; Lynch JC; Cairo MS; Smith LM; Hayashi RJ
    Am J Transplant; 2012 Nov; 12(11):3069-75. PubMed ID: 22883417
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course.
    Oertel S; Trappe RU; Zeidler K; Babel N; Reinke P; Hummel M; Jonas S; Papp-Vary M; Subklewe M; Dörken B; Riess H; Gärtner B
    Ann Hematol; 2006 Jul; 85(7):478-84. PubMed ID: 16586109
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risk Factors for and the Clinical Impact of Cytomegalovirus and Epstein-Barr Virus Infections in Pediatric Recipients of TCR-α/β- and CD19-Depleted Grafts.
    Laberko A; Bogoyavlenskaya A; Shelikhova L; Shekhovtsova Z; Balashov D; Voronin K; Kurnikova E; Boyakova E; Raykina E; Brilliantova V; Pirumova V; Novichkova G; Maschan A; Maschan M
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):483-490. PubMed ID: 28039080
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease.
    Meerbach A; Wutzler P; Häfer R; Zintl F; Gruhn B
    J Med Virol; 2008 Mar; 80(3):441-54. PubMed ID: 18205222
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [A clinical study of lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation].
    Xu LP; Huang XJ; Liu DH; Chen YH; Shi HX; Chen DB
    Zhonghua Nei Ke Za Zhi; 2007 Dec; 46(12):996-9. PubMed ID: 18478915
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Latest update on immunotherapy of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease].
    Hao QF; Sheng GY; Luan Z
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Sep; 15(9):795-9. PubMed ID: 24034931
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
    Loomis R; Carbone R; Reiss M; Lacy J
    Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy.
    Clave E; Agbalika F; Bajzik V; Peffault de Latour R; Trillard M; Rabian C; Scieux C; Devergie A; Socié G; Ribaud P; Adès L; Ferry C; Gluckman E; Charron D; Esperou H; Toubert A; Moins-Teisserenc H
    Transplantation; 2004 Jan; 77(1):76-84. PubMed ID: 14724439
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of six different specimen types for Epstein-Barr viral load quantification in peripheral blood of pediatric patients after heart transplantation or after allogeneic hematopoietic stem cell transplantation.
    Ruf S; Behnke-Hall K; Gruhn B; Bauer J; Horn M; Beck J; Reiter A; Wagner HJ
    J Clin Virol; 2012 Mar; 53(3):186-94. PubMed ID: 22182950
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Clinical Analysis of Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation in Severe Aplastic Anemia Patients].
    Yan HM; Zheng XL; Zhu L; Ding L; Han DM; Liu J; Xue M; Li S; Wang HX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1224-1229. PubMed ID: 35981389
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Successful treatment of EBV PTLD with CNS lymphomas with the monoclonal anti-CD20 antibody rituximab.
    Kordelas L; Trenschel R; Koldehoff M; Elmaagacli A; Beelen DW
    Onkologie; 2008 Dec; 31(12):691-3. PubMed ID: 19060508
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
    Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens.
    Chellapandian D; Das R; Zelley K; Wiener SJ; Zhao H; Teachey DT; Nichols KE;
    Br J Haematol; 2013 Aug; 162(3):376-82. PubMed ID: 23692048
    [TBL] [Abstract][Full Text] [Related]  

  • 58. EBV-specific T-cell immunity in pediatric solid organ graft recipients with posttransplantation lymphoproliferative disease.
    Wilsdorf N; Eiz-Vesper B; Henke-Gendo C; Diestelhorst J; Oschlies I; Hussein K; Pape L; Baumann U; Tönshoff B; Pohl M; Höcker B; Wingen AM; Klapper W; Kreipe H; Schulz TF; Klein C; Maecker-Kolhoff B
    Transplantation; 2013 Jan; 95(1):247-55. PubMed ID: 23222899
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation].
    Liu QF; Fan ZP; Luo XD; Zhang Y; Sun J
    Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(44):3123-6. PubMed ID: 19159594
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Clinical significance of Epstein-Barr Virus detection in the cerebrospinal fluid of patients who underwent hematopoietic stem cell transplantation].
    He Y; Ma R; Wang HF; Mo XD; Zhang YY; Lyu M; Yan CH; Wang Y; Zhang XH; Xu LP; Liu KY; Sun XJ; Huang YQ
    Zhonghua Xue Ye Xue Za Zhi; 2023 Sep; 44(9):737-741. PubMed ID: 38049317
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.